Kymera starts Phase 1 trial for KT-485, Sanofi pays $20 million

Kymera Therapeutics has begun its first-in-human Phase 1 clinical trial for the oral IRAK4 degrader, KT-485 (SAR447971), with the first participants now dosed. The trial is being conducted in partnership with Sanofi.

This milestone achievement triggered a $20 million payment from Sanofi to Kymera, according to the company. The Phase 1 study is evaluating KT-485 in both healthy adult volunteers and patients diagnosed with hidradenitis suppurativa.

Under their collaboration agreement, Sanofi will lead the development, regulatory, and commercialization efforts for the program. Kymera is eligible for potential milestone payments totaling up to $975 million, linked to clinical, regulatory, and commercial successes for KT-485.

KT-485 is Kymera's second-generation IRAK4 degrader, designed to target inflammatory diseases. The company highlights the significant need for novel oral therapies that can address key inflammatory pathways implicated in various immuno-inflammatory conditions.